Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
pharmaceuticals: Archive
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
REGNPositive Net Change ALNYPositive Net Change NVSNegative Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
REGNPositive Net Change LGNDPositive Net Change ANIPPositive Net Change RARENegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Top Analyst Reports for AstraZeneca, QUALCOMM & FedEx
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
AZNPositive Net Change QCOMNegative Net Change HALPositive Net Change AIGPositive Net Change FDXNegative Net Change BKRNegative Net Change
computers pharmaceuticals transportation
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.
JNJNegative Net Change PFEPositive Net Change NVONegative Net Change LLYNegative Net Change ABBVPositive Net Change
pharmaceuticals
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
SNYNegative Net Change AMRNNegative Net Change ANIPPositive Net Change KYMRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
by Zacks Equity Research
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
LGNDPositive Net Change ANIPPositive Net Change BPMCPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
by Zacks Equity Research
Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.
AMRNNegative Net Change ANIPPositive Net Change BHCNegative Net Change AMRXPositive Net Change
earnings medical pharmaceuticals
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
LGNDPositive Net Change ZTSNegative Net Change BPMCPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter 2024 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
UTHRPositive Net Change LGNDPositive Net Change CORTNegative Net Change ANIPPositive Net Change
pharmaceuticals
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
MRKNegative Net Change MRNANegative Net Change LGNDPositive Net Change ANIPPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
RHHBYPositive Net Change LGNDPositive Net Change SRPTPositive Net Change ANIPPositive Net Change
biotechs gene-therapy medical pharmaceuticals
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
GSKPositive Net Change BMYPositive Net Change GILDNegative Net Change EDITPositive Net Change DCPHNo Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
by Zacks Equity Research
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
REGNPositive Net Change SNYNegative Net Change BAYRYNo Net Change TSVTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
NVONegative Net Change LGNDPositive Net Change BPMCPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for May 2, 2024
by Zacks Equity Research
Companies In The News Are: CVS, PFE, PPL, ADP.
PPLPositive Net Change ADPNegative Net Change PFEPositive Net Change CVSPositive Net Change
business-services pharmaceuticals utilities
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
by Zacks Equity Research
Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue expectations.
PFEPositive Net Change LGNDPositive Net Change ANIPPositive Net Change BNTXPositive Net Change
pharmaceuticals
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
GSKPositive Net Change JNJNegative Net Change ANIPPositive Net Change VIRPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
by Sweta Killa
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
LLYNegative Net Change XLVPositive Net Change IYHPositive Net Change IHENegative Net Change PPHNegative Net Change MEDXPositive Net Change
earnings etfs pharmaceuticals
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
ALNYPositive Net Change ATRAPositive Net Change ARGXNegative Net Change ANNXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.
EXELNegative Net Change AMRNNegative Net Change ANIPPositive Net Change VYGRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for May 1, 2024
by Zacks Equity Research
Companies In The News Are: PYPL, LLY, MMM, GLW.
LLYNegative Net Change MMMPositive Net Change GLWPositive Net Change PYPLNegative Net Change
communications internet multi-sector-conglomerates pharmaceuticals
These 3 Companies Recently Lifted Guidance
by Derek Lewis
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture.
KOPositive Net Change LLYNegative Net Change ETNPositive Net Change
consumer-staples pharmaceuticals utilities
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
by Zacks Equity Research
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
NVONegative Net Change LLYNegative Net Change LGNDPositive Net Change ANIPPositive Net Change
pharmaceuticals
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
by Zacks Equity Research
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
REGNPositive Net Change PFEPositive Net Change NVONegative Net Change AMGNPositive Net Change MRNANegative Net Change
biotechs earnings gene-therapy immuno-therapy medical messenger-rna pharmaceuticals vaccines
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
AMZNPositive Net Change KOPositive Net Change LLYNegative Net Change MMMPositive Net Change SBUXNegative Net Change MCDNegative Net Change SMCIPositive Net Change
consumer-staples multi-sector-conglomerates pharmaceuticals restaurants